Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | SELE | P16581 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16748886 | 0.85 | L3MBTL1 (0.39) | L3MBTL1ICAM1SELEKDM4CNPC1 | |
| SCHEMBL15613482 | 0.85 | L3MBTL1 (0.48) | L3MBTL1ICAM1SELEKDM4CNPC1 | |
| SCHEMBL16886118 | 0.84 | L3MBTL1 (0.47) | L3MBTL1ICAM1SELEKDM4CNPC1 | |
| SCHEMBL16748887 | 0.84 | L3MBTL1 (0.47) | L3MBTL1ICAM1SELEKDM4CNPC1 | |
| SCHEMBL19490547 | 0.83 | L3MBTL1 (0.44) | L3MBTL1ICAM1SELEKDM4CNPC1 | |
| SCHEMBL18925730 | 0.77 | TEK (0.51) | L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15613768 | 0.77 | BTK (0.37) | L3MBTL1ICAM1SELE | |
| SCHEMBL16748885 | 0.76 | BTK (0.53) | — | |
| SCHEMBL21069390 | 0.72 | KDM4C (0.47) | L3MBTL1ICAM1SELEKDM4CNPC1 | |
| SCHEMBL2568655 | 0.72 | KDM4C (0.47) | L3MBTL1ICAM1SELEKDM4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| WO-2015074138-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | L3MBTL1 3544/4885ICAM1 1021/4885SELE 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.